Health Data Transfers | Global Overview 2025

Comparative Overview across Europe, the Americas, and Asia - and 2026-2027 Outlook

Clinical research, genomics, and connected health now rely on the global yet controlled circulation of data. The amount of health data exchanged across borders is growing exponentially: biobank records, genomic sequences, ePRO platforms, or AI-based clinical tools all multiply data flows between continents.

However, the rules governing cross-border transfers of health data vary widely from one jurisdiction to another. Each country defines its own concept of an ‘adequate level of protection,’ as well as the mechanisms and safeguards required to authorize international data sharing.

For stakeholders in the life-sciences ecosystem (pharmaceutical sponsors, CROs, university hospitals, medtech, and biotech start-ups) understanding these frameworks has become more than a compliance exercise, it is a strategic capability to secure partnerships, accelerate market access, and maintain trust with both regulators and patients.

1. Why International Data Transfers Are a Critical Issue

The globalization of clinical research has transformed how data travels and is processed. A single trial protocol may now involve investigational sites in Europe, central laboratories in North America, data storage in Asian data centers, and data-science teams distributed across time zones.

Health data therefore moves continuously between public and private entities in various forms: raw sequencing files (FASTQ, BAM), clinical results, images, metadata, or secondary-use research datasets. Due to its nature, health data is among the most sensitive categories of personal information. It can reveal not only a person’s medical status, but sometimes their unique genetic identity. As a result, most privacy frameworks impose strict conditions on any transfer outside national borders or the European Economic Area under the GDPR.

Poorly managed data transfers can have far-reaching consequences: regulatory delays (a trial authorization or inspection may be suspended if transfer documentation is incomplete), operational bottlenecks (missing contractual clauses or TIAs can delay analysis and publication), or legal and reputational risks (administrative fines, loss of partner confidence, reputational damage).

Conversely, a proactive and well-structured governance of data transfers can become a true performance enabler: it streamlines compliance during audits, reinforces legal certainty in global collaborations, and strengthens trust among authorities, investigators, and patients. In short, mastering cross-border data transfers is not only about mitigating risk, it is about enabling innovation in biomedical research to thrive within a trusted and sustainable framework.

2. Comparative Overview of Major Jurisdictions

Jurisdiction	Transfer Mechanisms / Authorizations	Health & Research Specificities	Practical Implications for International Trials
European Union (GDPR)	Adequacy decisions or SCCs/BCRs/derogations (Art. 49). TIA required.	Health data = special category (Art. 9).	Verify destination country + TOMs. Document transfer in register and DPIA.
United Kingdom (UK GDPR)	IDTA/Addendum. UK currently adequate under GDPR until 27^th December 2025 (review currently ongoing).	ICO guidance + NHS sector codes.	Harmonize SCCs/IDTA. Monitor for potential divergence from EU.
Switzerland (FADP 2023)	Adequate countries listed. Contractual clauses aligned with 2021 SCCs.	Extended protection for health and research data.	Sign Swiss clauses even if SCCs already in place.
United States	Data Privacy Framework (DPF) or SCCs + TIA.	HIPAA covers only certain entities; not all research data.	Check DPF certification. Evaluate security and cloud guarantees.
Canada	PIPEDA + provincial laws. Partial EU adequacy.	Public healthcare regimes often have separate data rules.	Include additional clauses on storage and reuse.
Brazil (LGPD)	Adequacy decisions in progress. Contractual clauses, consent, or specific agreements.	Transfer decree expected 2025-2026.	Follow publication of official clause templates. Adopt ANPD SCCs published in August 2025. Conduct partner audits. Monitor EU adequacy progress.
India (DPDP Act 2023)	Positive list of authorized countries (forthcoming).	No specific health regime, but sector considered sensitive.	Awaiting 2025 rules. Likely divergence from EU standards.
Australia (Privacy Act 1988)	APP 8 allows cross-border disclosure if the recipient upholds equivalent protection. No adequacy mechanism comparable to the EU model.	Health data = ‘sensitive information.’ Research uses allowed under consent or limited exceptions (e.g. public interest, de-identification).	Exporter remains accountable for breaches abroad. Include APP-compliance clauses and verify de-identification measures before transfer.

3. Key Areas to Watch (2026-2027)

United States: The Data Privacy Framework remains in force following upholding by the EU General Court in September 2025; periodic review anticipated.

India: Draft DPDP Rules published in 2025; final rules pending, with implementation decrees of the DPDP which may introduce localization obligations or transfer restrictions.

Africa: Data protection laws are being increasingly adopted (e.g., Kenya, Nigeria, Senegal), albeit with limited transfer mechanisms.

European Union: The EHDS Regulation entered into force in March 2025; implementation progresses towards unification of secondary-use frameworks. March 2027: Deadline for the Commission to adopt several key implementing acts, providing detailed rules for the regulation operationalization.

4. Strategic Recommendations for Health Sector Organizations

Map all actual data flows: raw, analytical, and derived data.
Conduct Transfer Impact Assessments (TIAs) aligned with EDPB guidance.
Standardize contractual frameworks (SCCs, IDTA, local addenda).
Anticipate regulatory convergence (EHDS, AI Act, ISO 27701, CEN/CENELEC health data standards).
Train R&D and clinical operations teams to identify when a transfer actually occurs (remote access, shared storage, cross-border analysis).

Conclusion

The globalization of clinical research demands robust governance of international data transfers. Although requirements differ across jurisdictions, their shared goal is to preserve trust in how health data is handled. Organizations that anticipate these evolving frameworks will turn compliance into a competitive advantage, enabling smoother collaborations, faster regulatory approvals, and stronger data value creation.

How MyData-TRUST Can Support You

Navigating international health data transfers requires more than legal awareness, it demands an integrated understanding of data protection, clinical operations, and regulatory expectations.

MyData-TRUST combines deep expertise, global privacy laws, and clinical research governance to help organizations build resilient and future-proof compliance strategies.

Our multidisciplinary teams, data protection officers, privacy lawyers, and life-science specialists, provide:

End-to-end support for assessing and documenting international data transfers (TIAs, SCCs, IDTA, BCRs).
Practical implementation guidance, ensuring privacy controls are aligned with both regulatory requirements and operational realities.

By partnering with MyData-TRUST, organizations can move from reactive compliance to proactive governance, transforming regulatory complexity into a competitive advantage and building the confidence needed to innovate responsibly in global health research.